multiple sclerosis

Sanofi SA (NASDAQ:SNY) reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis. What Happened: The company’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in...

Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD). Their recent publication in Nature's Scientific Reports highlights the use of Cannabis-Responsive (C-Res) biomarkers and...

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be...

In August 2011, Tim Cook was named the CEO of Apple Inc following the death of company CEO and co-founder Steve Jobs. Through the years, Cook has guided Apple to become one of the biggest companies in the world, with market capitalization now over $2.6 trillion. Here are five things you...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS). PAS002 vaccine construct encodes GlialCAM, a molecule found in the brain's white matter that is attacked in...

Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...

Novartis AG (NYSE: NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner. The biotechnology company is focused on the research and discovery of treatments for psychiatric and neurological...

Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling, the court also affirmed a decision by a review board within the U.S. Patent and Trademark office. "Viewing the...

The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS). Vumerity is next-generation fumarate with the established efficacy and well-characterized safety of Tecfidera (...

AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial. Following an interim analysis, Alexion says it will scrap a Phase 3 study...

Clene Inc (NASDAQ: CLNN) has shared positive top-line results from the Phase 2 REPAIR trials investigating the improvement of brain energetic metabolism in Parkinson's disease (PD) and multiple sclerosis (MS). The objective of the REPAIR program was to demonstrate the effects of...

Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's tyrosine kinase inhibitor (BTKi) for multiple sclerosis. InnoCare is eligible to receive up to $812.5 million in potential...

Verge Genomics has announced a three-year collaboration with Eli Lilly And Co (NYSE: LLY) to research and develop novel therapies to treat amyotrophic lateral sclerosis (ALS), a motor neuron disease. Under the terms of the three-year agreement, Verge will receive up to $25...

The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. ...